Vifian, Walter,Ratni, Hasane,Caroon, Joanie Marie,Dillon, Michael Patrick,Nettekoven, Matthias,Han, Bo
申请号：
AU2008203707
公开号：
AU2008203707B2
申请日:
2008.01.02
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
The present invention relates to a compound of formula (I) wherein Ris hydrogen or lower alkyl； R is lower alkyl, lower hydroxyalkyl or-(CHR)-A； R is hydrogen, lower alkyl or lowerhydroxyalkyl, or is heteroaryl optionally substituted by lower alkyl； A is cycloalkyl,aryl, heterocyclyl or heteroaryl, which rings are optionally substituted oneor more R, wherein R is lower alkyl, lower alkoxy, loweralkylsulfonyl, cyano, halogen, lower alkyl substituted by halogen or loweralkoxy substituted by halogen, or is aryl, heterocyclyl or heteroaryl optionallysubstituted by lower alkyl or is cycloalkyl optionally substituted by loweralkyl； x is 0, 1, 2 or 3； or R, R may form together with theN-atom heterocyclyl or heteroaryl, which rings are optionally substitutedby one or more substituents selected from the group consisting of lower alkyl,lower alkoxy, lower alkylsulfonyl, halogen, cycloalkyl, benzyl or aryl； Ris hydrogen or halogen； R is hydrogen or lower alkyl； Ris hydrogen, halogen or lower alkyl； m is 1 or 2； when m is 2, R may be thesame or not； n is 1 or 2； o is 1 or 2； when o is 2, R may be the same or not； orto a pharmaceutically suitable acid addition salt thereof. It has been foundthat the present compounds are high potential NK-3 receptor antagonists forthe treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia,anxiety and attention deficit hyperactivity disorder (ADHD).
